Specifically, we need to answer whether cimifugin could regulate initiative key factors, including TSLP and IL‐33, and their upstream regulators TJs derived from ECs and whether they could be adjustable targets in the treatment of AD. The gene discussed is IL33; the disease is Alzheimer disease.